Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.43 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | TP53 | P04637 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2372910 | 0.91 | LMNA (0.56) | LMNANPSR1PTPN1ALDH1A1TP53 | |
| SCHEMBL22917037 | 0.87 | LMNA (0.53) | LMNANPSR1CYP3A4KMT2ATRPM8 | |
| SCHEMBL7985518 | 0.81 | LMNA (0.51) | LMNANPSR1PTPN1KMT2AALDH1A1 | |
| SCHEMBL7985338 | 0.77 | KMT2A (0.54) | LMNANPSR1KMT2ATRPM8ALDH1A1 | |
| SCHEMBL12501297 | 0.76 | LMNA (0.46) | LMNANPSR1PTPN1ALDH1A1TP53 | |
| SCHEMBL7978939 | 0.74 | LMNA (0.49) | LMNANPSR1KMT2AALDH1A1TP53 | |
| SCHEMBL23031991 | 0.74 | LMNA (0.49) | LMNANPSR1CYP3A4KMT2ATRPM8 | |
| SCHEMBL21127506 | 0.74 | ALDH1A1 (0.41) | LMNACYP3A4KMT2ATRPM8ALDH1A1 | |
| SCHEMBL1955058 | 0.74 | LMNA (0.44) | LMNANPSR1PTPN1ALDH1A1MAPT | |
| SCHEMBL8061230 | 0.74 | LMNA (0.44) | LMNANPSR1PTPN1ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2699241-B1 | ANTIVIRAL COMPOUNDS | PROSETTA ANTIVIRAL INC (US) | 2016-07-27 | — | — | EP | disclosed |
| EP-2585073-B1 | ANTIVIRAL COMPOUNDS | PROSETTA ANTIVIRAL INC (US) | 2016-04-27 | — | — | EP | disclosed |
| US-8828986-B2 | Antiviral compounds | PROSETTA ANTIVIRAL INC. (US) | 2014-09-09 | — | — | US | disclosed |
| US-8785434-B2 | Antiviral compounds | PROSETTA ANTIVIRAL INC. (US) | 2014-07-22 | — | — | US | disclosed |
| EP-2699241-A1 | ANTIVIRAL COMPOUNDS | Prosetta Antiviral Inc. (US) | 2014-02-26 | — | — | EP | disclosed |
| WO-2012145567-A1 | ANTIVIRAL COMPOUNDS | PROSETTA ANTIVIRAL INC. (US) | 2012-10-26 | — | — | WO | disclosed |
| US-20120270854-A1 | Antiviral Compounds | PROSETTA ANTIVIRAL INC. (US) | 2012-10-25 | — | — | US | disclosed |
| US-20120157435-A1 | Antiviral Compounds | PROSETTA ANTIVIRAL INC. (US) | 2012-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120157435-A1 | Antiviral Compounds | MAVS, ZC3HAV1, EIF2AK2 | LMNA 1442/4885NPSR1 3601/4885CYP3A4 2548/4885 |
| US-20120270854-A1 | Antiviral Compounds | HAVCR2, MAVS, EIF2AK2 | LMNA 966/4885NPSR1 3933/4885CYP3A4 2735/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.